Genmab's Encouraging Oncology Data Boosts Investor Optimism

Stifel reiterated a Buy rating and $157 price target for Incyte (INCY) after positive cancer drug trial data. The stock trades at $115.77 with a P/E of 14.66 and PEG of 0.18. Analysts highlight INCB734's potential in pancreatic and colorectal cancer, with key data expected in 2027-2028. Other analysts also commented on Incyte's pipeline, with varied price targets and ratings.

BMO Capital reiterated a Market Perform rating on Incyte (INCY) with a $130 price target, citing progress in its solid-tumor pipeline. The firm highlighted encouraging data on INCA33890 and INCB161734, supporting Phase 3 development. Phase 3 readouts are expected in 2028. Analysts have varying price targets, ranging from $86 to $157. Other firms also commented positively on Incyte's oncology pipeline and clinical trials.

H.C. Wainwright maintained a Buy rating and $152 price target for Incyte (INCY) after positive clinical trial results for its cancer drug INCB161734. The stock, currently at $113.31, shows attractive valuation metrics. Other analysts have mixed views, with UBS raising its target to $127 and Morgan Stanley initiating coverage with a $119 target.

J.P. Morgan upgraded Genmab to 'overweight' and raised its price target to DKr3,500, citing expected positive results from a late-stage trial of its cancer drug petosemtamab. The brokerage anticipates a response rate of at least 40% in head and neck cancer patients, raising its peak sales forecast to $5 billion. It also increased sales forecasts for other drugs, Rina-S and Epkinly, and adjusted its revenue and earnings per share estimates.

JPMorgan upgraded Genmab (GMAB) to Overweight, raising its price target to DKK3,500. The move follows a 68% stock surge and ahead of a key Phase III trial readout. JPMorgan expects a positive outcome and raised peak sales forecasts for peto to $5B. Genmab reported 25% revenue growth in H1 and exceeded earnings estimates.

Incyte (NASDAQ:INCY) reported promising early data for its cancer treatments '890 and '734. '890 showed a 71% response rate in GI cancer patients, with ongoing phase III trials expected to report in 2029. '734 demonstrated high response rates in pancreatic and colorectal cancers, with phase III trials planned. Incyte is exploring additional combinations and indications for both drugs.